Results 11 to 20 of about 801 (115)
Second generation antipsychotics causing neuroleptic malignant syndrome
Sri Lanka Journal of Psychiatry, 2016 Neuroleptic malignant syndrome (NMS) is a rare yet potentially lethal medical emergency encountered by psychiatrists. NMS is commonly associated with potent first generation antipsychotics, especially haloperidol and fluphenazine. However, there are many
C. Suraweera, R. Hanwella, V. De Silva
doaj +1 more source
A meta-analysis of the efficacy of second-generation antipsychotics [PDF]
Schizophrenia Research, 2003 Consensus panel recommendations regarding choice of an antipsychotic agent for schizophrenia differ markedly, but most consider second-generation antipsychotics (SGAs) as a homogeneous group. It has been suggested that SGAs seem falsely more efficacious than first-generation antipsychotics (FGAs) as a result of reduced efficacy due to use of a high ...
John M, Davis, Nancy, Chen, Ira D, Glick
openaire +2 more sources
Longitudinal Gut Microbiota Dysbiosis Underlies Olanzapine-Induced Weight Gain
Microbiology Spectrum, 2023 Olanzapine is one of the most effective medicines available for stabilizing schizophrenia spectrum disorders. However, it has been reported to show the greatest propensity for inducing body weight gain and producing metabolic side effects, which cause a ...
Li Qian +10 more
doaj +1 more source
A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers
Psychiatry and Clinical Psychopharmacology, 2018 OBJECTIVES: The duration of life of patients with schizophrenia is shorter than that of the general population for various reasons. Especially cardiovascular diseases are one of the most important causes of death in patients with schizophrenia.
Demet Sağlam Aykut +1 more
doaj +1 more source
The effects of antipsychotic medications on microbiome and weight gain in children and adolescents
BMC Medicine, 2019 Background Atypical antipsychotics, also known as second-generation antipsychotics, are commonly prescribed as treatment for psychotic disorders in adults, as well as in children and adolescents with behavioral problems.
Tali Bretler +3 more
doaj +1 more source
Pathophysiology and management of risperidone-induced sialorrhea: case report
Frontiers in Psychiatry, 2023 BackgroundAmong antipsychotics, sialorrhea is most associated with clozapine, and when it occurs, it is uncomfortable, socially stigmatizing, and can contribute to medication non-adherence.
Tyler Torrico +2 more
doaj +1 more source
Managing acute agitation and aggression in the world of drug shortages [PDF]
Mental Health Clinician, 2021 Acute agitation and aggression create safety risks for both patients and staff, often leading to psychiatric emergencies. Quick and appropriate treatment is necessary to achieve safe and effective outcomes.
Jennifer Miller, PharmD, BCPP
doaj +1 more source
Aripirazole-Long Acting Injectable in Pregnant Women with Schizophrenia: A Case Series
European Psychiatry, 2022 Introduction Long-acting injectable antipsychotics (LAIs) have emerged as a new therapeutic option to treat patients suffering a psychotic disorder. To date, there is a lack of studies regarding safety and clinical use pattern of LAIs in pregnant women.
B. Fernández-Abascal +3 more
doaj +1 more source
Akathisia and second-generation antipsychotic drugs
Current Opinion in Psychiatry, 2009 Akathisa is one of the most common and distressing neuroleptic-induced extrapyramidal side effects. Although it is well recognized in the context of conventional antipsychotic medications, there have been recent concerns raised by clinicians and researchers that this syndrome is overlooked in relation to second-generation or atypical antipsychotics ...
Kumar, Rajeev, Sachdev, Perminder Singh
openaire +3 more sources